Announcement
Announcement under Regulation 30 (LODR)-Allotment 17 Sep - Allotted 70 lakh convertible warrants to promoter group at Rs 196 each, raising Rs 34.3 crore.
Source: Bse
Ind-Swift Laboratories Limited (INDSWFTLAB)
Small CapPharma stocks · Small cap · NSE
Ind-Swift Laboratories Limited operates in API, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result16 Aug, 01:42 am IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
75BullishSMA20 +3.8% / mo · MACD − · sector +4.9pp vs Nifty 500 (3M)
Stock trend: 59
Sector RS: 100
Sector 3M: -0.7% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
INDSWFTLABD candles · FIT view+155.0%Latest close ₹342.50 on 2026-10-21
Bar
-3.0%
RSI
39
MACD hist
-6.93
52W pos
76%
2026-10-21O ₹353.00H ₹366.00L ₹336.80C ₹342.50Vol 6.4L sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
INDSWFTLABNifty PharmaNifty 500
- INDSWFTLAB
- +44.1%
- Nifty 500
- -6.5%
- Nifty Pharma
- -2.0%
- Vs Nifty 500
- +50.6 pp
Chart stats
21 Oct 2026- From 52W high
- -19.4%
- 52W range position
- 76%
- ATR (14)
- 6.5%
- Volume vs 20D
- 1.12x
- Avg traded value
- ₹22 Cr
- 20D price channel
- ₹336.8 - ₹424.8
₹424.8
₹87.2 - ₹424.8
₹22.4
Latest completed session
20-session average
49.0% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · WATCHLIST34
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Excellent100
Revenue +24.8% · PAT +177.8% YoY
Technical
Bullish75
Price trend and sector-relative-strength timing.
Valuation
Legacy model-13.1%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence61
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Excellent · 100/100Rev +25% YoY · PAT +178% YoY · margin expansion · +12% QoQ · operating leverage
Filed 30 Jun 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹191 Cr | +24.8% | +12.3% |
| EBITDA | ₹33 Cr | +725.0% | +57.1% |
| Operating margin | 17.0% | +1460 bps | +500 bps |
| PAT | ₹25 Cr | +177.8% | +66.7% |
| PAT margin | 13.1% | +721 bps | +427 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 51.50
- P/B
- 2.43
- EV/EBITDA
- 36.66
- Market Cap
- 3355.00Cr
Profitability
- ROE
- 4.02%
- ROCE
- 4.86%
- ROA
- 3.41%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- -6.00%
- EPS 5Y
- 79.00%
- Revenue 3Y
- -19.00%
- EPS 3Y
- -6.00%
Balance Sheet
- Debt/Equity
- 0.01
- Interest Coverage
- 60.00×
- Altman Z
- 7.90
- Book Value
- 159.00
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 8/5
- OCF
- -68.00 Cr
- EPS TTM
- 6.73
Shareholding
- Promoter Hold
- 42.93%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 88%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 191+12.4% vs prev
Net Profit
₹ CrLatest: 25.0+66.7% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term uptrend intact. RSI 39. Wait for confirmation.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 rising (~3.7% over last month) — short-term momentum positive.
- RSI(14) at 39 — falling, no extreme reading.
- MACD below signal but histogram contracting — bearish momentum easing.
- 19% off 52W high · 293% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
98
RS percentile
Stage 2 UptrendEstablished S2
1M return
-9.7%
3M return
+44.1%
6M return
+148.2%
1Y return
+232.4%
RS 1D
0
RS 20D
-1
Sector rank
#1
Industry rank
#9
Stage evidence
- Price is 46.1% above the 30-week proxy.
- The 50-DMA is above the 30-week proxy and its slope is rising +15.8%.
- Both 3-month and 6-month returns are positive.
50-DMA
price below
200-DMA
price above
S2 entered
12 Feb 2026
S2 age
177 trading sessions
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
21 Oct 2026Value 371.18-1.77%
RS vs Nifty 500371
Valuation & peers
U-Score 34 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Valuation & peers
U-Score 34 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
WATCHLIST
Fundamental score breakdown
U band · WATCHLISTValuation2/30
Growth16/25
Quality0/20
Balance Sheet11/15
Cash Flow3/10
Piotroski
5/9 (+3)
Penalties
-1
Raw sum
34
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
34/100 · legacy band WATCHLIST
Positive drivers
- Balance sheet contributes 11/15 to the score.
- Growth contributes 16/25 to the score.
- Cash flow contributes 3/10 to the score.
Main drags
- Penalty bucket subtracts 1 points.
- Fair-value margin of safety is negative at -13.1%.
- Quality is weaker at 0/20; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
51.5
PB
2.4
EV/EBITDA
36.7
ROE
4.0%
ROCE
4.9%
FCF Yield
—
Debt/Equity
0.0
MoS
-13.1%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
34
Previous: 34
Legacy U-Score band
WATCHLIST
Previous: WATCHLIST
Margin of safety
-13.1%
Previous: -16.2%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
34
34
34
34
34
34
34
34
34
34
34
34
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹155.17
-120.7% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹302.85
-13.1% MoS
PEG
0.65
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
NGLFINE
Small
NGL Fine-Chem Limited
Pharmaceuticals
match 163
38
32.3
17.4%
-339%
WATCHLIST
GUJTHEM
Small
Gujarat Themis Biosyn Limited
Pharmaceuticals
match 163
26
99.7
—
-86%
OVERVALUED
ARVEE
Small
Arvee Laboratories (India) Limited
Pharmaceuticals
match 157
16
57.0
7.3%
-736%
OVERVALUED
LASA
Small
Lasa Supergenerics Limited
Pharmaceuticals
match 156
5
—
-19.7%
—
OVERVALUED
INFINIUM
SME
Infinium Pharmachem Ltd.
Pharmaceuticals
match 153
36
39.1
10.5%
+16%
WATCHLIST
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Ind-Swift Laboratories Limited operates in API, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
61Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 32nd percentile of the scored universe and 22nd percentile within Pharma. Main check: financial discipline is weak at 30/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
15 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
32nd percentile
overall median 67 · Pharma: 22nd pctile, median 70 · Small: 36th pctile, median 66
Evidence depth
Financial-only
15 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
82
strong · holding, pledge, alignment
Cash flow
52
watch · profit to cash conversion
Balance sheet
96
strong · leverage and solvency
Discipline
30
weak · capital discipline
Results
43
weak · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸Promoter holding increased 3.4%.
- ▸8 years of positive FCF.
- ▸Debt/equity is 0.01.
Trust risks
- ▸Operating cash flow is negative at ₹-70 Cr.
- ▸2 latest quarters had PAT decline worse than 25% YoY.
- ▸ROCE is low at 4.7%.
- ▸ROE is low at 3.9%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Ind-Swift Laboratories Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 6 Sep
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 4 Sep - Please refer attached newspaper publication dated 04.09.2026.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Press Release / Media Release 18 Aug - Jammu facility upgrade to EU-GMP/PICS with ₹45 crore investment, targeting ₹100 crore revenue from FY30.
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2025
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.